HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Meets Initial Deadlines In OTC Monograph Overhaul While It's Rebuilding The Program

Executive Summary

Authorization was a long time coming for FDA to reform OTC monograph program and streamline process to change formulations, indications or labeling for large majority of drugs available nonprescription. As program is overhauled, monograph updates may seem to be coming just as slowly.

You may also be interested in...



OTC Monograph User Fees Grow In FDA FY2023 Budget Request And In Industry's Thinking

Stakeholders didn’t indicate extensive familiarity with OTC monograph user fees during online workshop. Biden administration’s FDA FY2023 budget request includes $5m increase to $30.36m in facility registration fees required from all firms manufacturing OTC monograph drugs available in US.

US FDA OTC Monograph Meetings Guidance Should Be Familiar To Firms Using NDA Pathway

Recent draft guidance on scheduling FDA meetings to discuss potential OTC monograph order requests marks step in program overhaul authorized in 2020 legislation, but isn’t a signal for manufacturers, other industry stakeholders to expect meetings soon.

Califf Returns To US FDA Helm As Familiar Consumer Health Regulation Problems Continue

Announcement of Senate confirmation of Robert Califf as commissioner came shortly after FDA announced recalls of products labeled as supplements but spiked with ED drugs. Like those and others recently identified as adulterated, supplements with undisclosed drugs were being found during Califf’s first stint in 2016 and 2017.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel